Recordati SpA (MIL:REC) Stock Based Compensation: €17 Mil (TTM As of Mar. 2026)


MIL:REC Recordati SpA MIL:REC
94 GF Score
Price €51.35
GF Value €60.74
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Recordati SpA Stock Based Compensation?

Recordati SpA MIL:REC -0.48% 94 Stock Based Compensation is €17 Mil as of Mar. 2026. GuruFocus rates MIL:REC with a GF Score™ of 94/100 and a GF Value™ of €60.74 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Recordati SpA's Stock Based Compensation for the three months ended in Mar. 2026 was €5 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €17 Mil.

Recordati SpA Stock Based Compensation Related Terms

Recordati SpA Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Recordati SpA's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recordati SpA Stock Based Compensation Chart

Recordati SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.08 8.25 10.87 16.52 16.55

Recordati SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.98 4.96 3.25 4.36 4.76
MIL:REC
94GF Score
Recordati SpA MIL:REC
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recordati SpA Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €17 Mil.

What does a Stock Based Compensation of €17 Mil mean?
Recordati SpA (MIL:REC) has a Stock Based Compensation of €17 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Recordati SpA and its competitors.
Is Recordati SpA's Stock Based Compensation too high?
Recordati SpA's current Stock Based Compensation is €17 Mil. Overall, Recordati SpA has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Stock Based Compensation compare to LLY and JNJ?
Recordati SpA's Stock Based Compensation of €17 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Recordati SpA and its competitors. Recordati SpA's current Stock Based Compensation is €17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.74, compared to a current price of €51.35 — trading 15.5% below its estimated fair value. The current Stock Based Compensation is €17 Mil. Recordati SpA's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Stock Based Compensation is €17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recordati SpA (MIL:REC) Overvalued in 2026?

Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued. The current stock price of €51.35 is trading 15.5% below its estimated GF Value™ of €60.74. GuruFocus considers Recordati SpA to be Modestly Undervalued.

Key valuation signals for MIL:REC:

  • Stock Based Compensation: €17 Mil
  • GF Value™: €60.74 vs. price of €51.35 (15.5% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recordati SpA Business Description

Address Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
94GF Score

Get the complete analysis for MIL:REC

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.35
Price
€60.74
GF Value